Four months before FDA’s vaccine advisers voted unanimously yesterday to back Moderna’s first mRNA flu shot, the same agency had refused to even read the file. The reason then was specific and on the record: the pivotal trial had measured the vaccine against the wrong comparator. The vote moved. The comparator did not.
The Vaccines and Related Biological Products Advisory Committee voted 9-0 on June 18 that the benefits of MFLUSIVA (formerly mRNA-1010) outweigh the risks for adults aged 50 to 64 and for those 65 and older. FDA’s formal decision is due August 5. If it goes Moderna’s way, this becomes the first mRNA-based seasonal flu vaccine licensed in the United States. That headline is the easy part to write. The hard part is the trial design that should have made it impossible.
In a Phase 3 study of 40,805 adults (Study P304, NCT06602024), Moderna tested mRNA-1010 against a licensed standard-dose flu shot and reported a 26.6% relative efficacy edge against PCR-confirmed influenza-like illness in people 50 and older, plus a 47.9% edge on healthcare-utilization outcomes like ER visits and hospitalizations. Those are the kinds of numbers a Phase 3 program hopes to land on, and they are the exact numbers that nonetheless got the application bounced.
On February 3, FDA’s top vaccine official, Vinay Prasad, personally signed a refusal-to-file letter saying the trial wasn’t “adequate and well-controlled.” His objection was not about safety. It was not about efficacy. It was about who the vaccine was compared against. For Americans 65 and older, the standard-dose flu shot has not been the recommended product since 2022, when ACIP issued a preferential recommendation for high-dose Fluzone, adjuvanted Fluad, or recombinant Flublok, because older immune systems respond poorly to standard-dose vaccines. Beating standard-dose in that population, Prasad’s letter argued, is beating the weaker of two available standards. If you want to know whether your new shot is better than what grandma is actually getting at the pharmacy, you have to test it against what she is actually getting at the pharmacy.
The agency reversed within days and accepted Moderna’s filing. Nothing about the underlying trial changed. The same standard-dose comparator data is what the advisory committee voted on yesterday. The comparator concern the agency itself put in writing in February was, by June, a footnote in the briefing materials.
That was not the only outstanding question. FDA reviewers flagged a list of others for the panel before the vote: efficacy data covers only a single flu season; there is no data on the B/Victoria lineage because that strain barely circulated during the trial year; no data in immunocompromised patients; no data in the very frail elderly; no co-administration data with COVID-19 or RSV vaccines, which is how flu shots are now routinely given. The vaccine’s formulation still contains an antigen against B/Yamagata for stability reasons, even though B/Yamagata has not been detected in global surveillance since the early COVID period.
Then there is reactogenicity, the part of this story most likely to land on the patient sitting in the pharmacy chair. mRNA platforms hit harder than inactivated egg-based flu shots. In the Phase 3 safety data, injection-site pain ran 65.8% with mRNA-1010 versus 29.8% with the standard-dose comparator. Fatigue, headache, and muscle pain were all more common with the mRNA shot. Mostly mild to moderate, mostly transient, no excess serious adverse events on record. That is the same family of side-effect profile most Americans already know from their COVID boosters: the day-after slog. Several VRBPAC members said openly during the meeting that Moderna will have to do real work explaining to patients why they should pick a shot that may make them feel worse for a day or two than the one they have been getting for years.
The COVID rollout already taught us how that conversation tends to go. The day-after symptoms became a cultural reference point, and the institutional response settled into a familiar shape: tell people the side effects mean the vaccine is “working,” tell them to take acetaminophen, change the subject. What rarely happened was a direct adult conversation about whether the trade-off was worth it for that person, that pathogen, that season. The mRNA flu vaccine is going to need that conversation. Flu is not COVID. Most healthy adults under 65 do not have serious flu outcomes in a typical year, and the argument for swapping a familiar shot with a 30% sore-arm rate for a new shot with a 66% sore-arm rate, in exchange for roughly a one-quarter relative reduction in flu-like illness measured over a single season against a comparator the agency itself had flagged, is one that has to be made to patients with specifics, not with the historic-first headline.
So what happens next. The PDUFA decision is August 5. If FDA approves, ACIP picks up the recommendation question this fall, and the high-dose comparator argument Prasad made in February gets aired again in front of a different audience with different stakes. Moderna will push hard on the 47.9% healthcare-outcome edge, which reads stronger than the 26.6% all-comers number. Real-world surveillance from the 2026-27 season will either confirm the trial picture or complicate it, particularly on B/Victoria and on the still-unaddressed comparison against high-dose vaccine in the population that actually needs the protection. And reactogenicity is the variable that will move uptake, because patients pay attention to how they feel.
The advisers gave the shot a unanimous vote. The questions that bounced the application back in February are still sitting on the table in full view. Which set of facts shapes what gets injected into American arms next flu season is the part that has not been decided yet.
Sources
- BioPharma Dive – FDA’s Vinay Prasad signs refusal-to-file letter to Moderna over comparator (Feb 2026)
- Fierce Biotech – FDA accepts Moderna flu vaccine filing after swift U-turn
- Fierce Biotech – Amenable FDA briefing docs ahead of VRBPAC adcomm
- Vaccine (ScienceDirect) – Phase 3 safety and immunogenicity trial of mRNA-1010 vs standard-dose comparator
- STAT – FDA advisory panel endorses Moderna mRNA flu vaccine that was subject of controversy
- Medical Daily – VRBPAC vote, reactogenicity figures, B/Yamagata formulation
- Pharmacy Times – FDA declines to review mRNA-1010 application, citing comparator concerns
- The Hill – FDA panel recommends Moderna mRNA flu vaccine for older adults
- CDC – ACIP influenza vaccine recommendations (preferential recommendation for higher-dose/adjuvanted/recombinant vaccines in adults 65+, since 2022)